Abstract
Few studies have examined probiotic prophylaxis in patients with acute pancreatitis, and those that have been performed have yielded conflicting results. In this Practice Point commentary, I discuss the findings and limitations of a study by Besselink et al., which assessed the effects of a multispecies probiotic preparation in patients with predicted severe acute pancreatitis. The preparation did not reduce infectious complications, and increased mortality. However, it is necessary to remember that large genetic and functional differences exist between various strains of bacteria and that only a few lactic acid bacteria (LAB) have demonstrated an ability to significantly reduce inflammation, control infection and provide health benefits to humans. Choice of LAB and dose of LAB is critical for outcome. Extensive preclinical studies are essential before recommendations for new cocktails of probiotics can be introduced in clinical practice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Nature Clinical Practice Gastroenterology & Hepatology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
